| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO
1 company
Kenneth Allen Myszkowski last filed a Form 4 in January 2025, as Chief Financial Officer at ARWR. From March 2015 to January 2025, the filings on record show 0 open-market purchases and 23 sales. Kenneth Allen Myszkowski's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Kenneth Allen Myszkowski's trades have earned a middling insider score of 68/100 across 7 rated trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of -2.3%.
At the last filing, the largest reported position was 455,433 shares of ARWR. The ARWR filings lean toward selling, a net 669,053 shares.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2018 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 20,000 | $8.00 | $160,000.00 | -6.0% | |
| Aug 23, 2016 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 20,000 | $8.00 | $160,000.00 | -14.7% | |
| Dec 30, 2015 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 23,347 | $6.13 | $143,117.11 | -21.5% |